649 related articles for article (PubMed ID: 30670413)
1. Dose Selection and Validation for Ceftazidime-Avibactam in Adults with Complicated Intra-abdominal Infections, Complicated Urinary Tract Infections, and Nosocomial Pneumonia.
Das S; Li J; Riccobene T; Carrothers TJ; Newell P; Melnick D; Critchley IA; Stone GG; Nichols WW
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670413
[TBL] [Abstract][Full Text] [Related]
2. Clinical Pharmacokinetics and Pharmacodynamics of Ceftazidime-Avibactam Combination: A Model-Informed Strategy for its Clinical Development.
Sy SKB; Zhuang L; Sy S; Derendorf H
Clin Pharmacokinet; 2019 May; 58(5):545-564. PubMed ID: 30097887
[TBL] [Abstract][Full Text] [Related]
3. Population Pharmacokinetic Modeling and Probability of Pharmacodynamic Target Attainment for Ceftazidime-Avibactam in Pediatric Patients Aged 3 Months and Older.
Franzese RC; McFadyen L; Watson KJ; Riccobene T; Carrothers TJ; Vourvahis M; Chan PLS; Raber S; Bradley JS; Lovern M
Clin Pharmacol Ther; 2022 Mar; 111(3):635-645. PubMed ID: 34687548
[TBL] [Abstract][Full Text] [Related]
4. Selecting the dosage of ceftazidime-avibactam in the perfect storm of nosocomial pneumonia.
Das S; Zhou D; Nichols WW; Townsend A; Newell P; Li J
Eur J Clin Pharmacol; 2020 Mar; 76(3):349-361. PubMed ID: 31836928
[TBL] [Abstract][Full Text] [Related]
5. Considerations in the Selection of Renal Dosage Adjustments for Patients with Serious Infections and Lessons Learned from the Development of Ceftazidime-Avibactam.
Li J; Lovern M; Riccobene T; Carrothers TJ; Newell P; Das S; Talley AK; Tawadrous M
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015049
[TBL] [Abstract][Full Text] [Related]
6. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study.
Carmeli Y; Armstrong J; Laud PJ; Newell P; Stone G; Wardman A; Gasink LB
Lancet Infect Dis; 2016 Jun; 16(6):661-673. PubMed ID: 27107460
[TBL] [Abstract][Full Text] [Related]
7. Ceftazidime-Avibactam Population Pharmacokinetic Modeling and Pharmacodynamic Target Attainment Across Adult Indications and Patient Subgroups.
Li J; Lovern M; Green ML; Chiu J; Zhou D; Comisar C; Xiong Y; Hing J; MacPherson M; Wright JG; Riccobene T; Carrothers TJ; Das S
Clin Transl Sci; 2019 Mar; 12(2):151-163. PubMed ID: 30221827
[TBL] [Abstract][Full Text] [Related]
8. Ceftazidime-avibactam for the treatment of complicated urinary tract infections and complicated intra-abdominal infections.
Mawal Y; Critchley IA; Riccobene TA; Talley AK
Expert Rev Clin Pharmacol; 2015; 8(6):691-707. PubMed ID: 26420166
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of ceftazidime/avibactam against urinary isolates from patients in a Phase 3 clinical trial programme for the treatment of complicated urinary tract infections.
Stone GG; Bradford PA; Yates K; Newell P
J Antimicrob Chemother; 2017 May; 72(5):1396-1399. PubMed ID: 28088768
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic and Pharmacodynamic Analysis of Ceftazidime/Avibactam in Critically Ill Patients.
Stein GE; Smith CL; Scharmen A; Kidd JM; Cooper C; Kuti J; Mitra S; Nicolau DP; Havlichek DH
Surg Infect (Larchmt); 2019 Jan; 20(1):55-61. PubMed ID: 30351195
[TBL] [Abstract][Full Text] [Related]
11. Monte Carlo Simulation Methodologies for β-Lactam/β-Lactamase Inhibitor Combinations: Effect on Probability of Target Attainment Assessments.
Kidd JM; Stein GE; Nicolau DP; Kuti JL
J Clin Pharmacol; 2020 Feb; 60(2):172-180. PubMed ID: 31423601
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Determine Optimal Dosing of Ceftazidime-Avibactam for the Treatment of Acute Pulmonary Exacerbations in Patients with Cystic Fibrosis.
Bensman TJ; Wang J; Jayne J; Fukushima L; Rao AP; D'Argenio DZ; Beringer PM
Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28784670
[TBL] [Abstract][Full Text] [Related]
13. Focus on ceftazidime-avibactam for optimizing outcomes in complicated intra-abdominal and urinary tract infections.
Nicolau DP
Expert Opin Investig Drugs; 2015; 24(9):1261-73. PubMed ID: 26145447
[TBL] [Abstract][Full Text] [Related]
14. Spotlight on ceftazidime/avibactam: a new option for MDR Gram-negative infections.
Falcone M; Paterson D
J Antimicrob Chemother; 2016 Oct; 71(10):2713-22. PubMed ID: 27432599
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic drug evaluation of avibactam + ceftazidime for the treatment of hospital-acquired pneumonia.
Falcone M; Viale P; Tiseo G; Pai M
Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):331-340. PubMed ID: 29373935
[TBL] [Abstract][Full Text] [Related]
16. Ceftazidime/avibactam: a novel cephalosporin/nonbeta-lactam beta-lactamase inhibitor for the treatment of complicated urinary tract infections and complicated intra-abdominal infections.
Hidalgo JA; Vinluan CM; Antony N
Drug Des Devel Ther; 2016; 10():2379-86. PubMed ID: 27528799
[TBL] [Abstract][Full Text] [Related]
17. Steady-State Ceftazidime-Avibactam Serum Concentrations and Dosing Recommendations in a Critically Ill Patient Being Treated for Pseudomonas aeruginosa Pneumonia and Undergoing Continuous Venovenous Hemodiafiltration.
Soukup P; Faust AC; Edpuganti V; Putnam WC; McKinnell JA
Pharmacotherapy; 2019 Dec; 39(12):1216-1222. PubMed ID: 31596506
[TBL] [Abstract][Full Text] [Related]
18. Avibactam Pharmacokinetic/Pharmacodynamic Targets.
Nichols WW; Newell P; Critchley IA; Riccobene T; Das S
Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29610208
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological aspects and spectrum of action of ceftazidime-avibactam: a systematic review.
Tuon FF; Rocha JL; Formigoni-Pinto MR
Infection; 2018 Apr; 46(2):165-181. PubMed ID: 29110143
[TBL] [Abstract][Full Text] [Related]
20. Ceftazidime-Avibactam: A Review in the Treatment of Serious Gram-Negative Bacterial Infections.
Shirley M
Drugs; 2018 Apr; 78(6):675-692. PubMed ID: 29671219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
